These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 37451749)

  • 1. Pediatric Neuromyelitis Optica Spectrum Disorder.
    Poisson K; Moeller K; Fisher KS
    Semin Pediatr Neurol; 2023 Jul; 46():101051. PubMed ID: 37451749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlap syndrome of anti-aquaporin 4 positive neuromyelitis optica spectrum disorder and primary Sjögren's syndrome: a systematic review of individual patient data.
    Prasad CB; Kopp CR; Naidu G; Sharma V; Misra DP; Agarwal V; Sharma A
    Rheumatol Int; 2024 Dec; 44(12):2807-2815. PubMed ID: 37500817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
    Rajput HM; Hassan M; Badshah M
    Mult Scler Relat Disord; 2023 Jun; 74():104656. PubMed ID: 37068371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.
    Huang W; Tan H; Xia J; Li W; Li X; ZhangBao J; Chang X; Wang L; Wang M; Zhao C; Lu J; Lu C; Dong Q; Zhou L; Quan C;
    Mult Scler Relat Disord; 2022 Oct; 66():104023. PubMed ID: 35843144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders.
    Camera V; Messina S; Elhadd KT; Sanpera-Iglesias J; Mariano R; Hacohen Y; Dobson R; Meletti S; Wassmer E; Lim MJ; Huda S; Hemingway C; Leite MI; Ramdas S; Palace J
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):101-111. PubMed ID: 34583946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
    Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
    Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
    Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
    Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study.
    Solmaz I; Öncel IH; Konuşkan B; Erol I; Orgun LT; Yılmaz Ü; Ünalp A; Atasoy E; Aksoy E; Yılmaz D; Öztürk M; Karaca NB; Yılmaz S; Yiş U; Dündar NO; Parlak Ş; Vural A; Günbey C; Anlar B
    Mult Scler Relat Disord; 2023 Sep; 77():104847. PubMed ID: 37393803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder.
    Zhou Y; Zhong X; Shu Y; Cui C; Wang J; Wang Y; Li X; Chen Z; Peng L; Kermode A; Qiu W
    Mult Scler Relat Disord; 2019 Feb; 28():213-220. PubMed ID: 30623860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
    Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
    Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.
    Martín-Nares E; Hernandez-Molina G; Fragoso-Loyo H
    Lupus; 2019 Oct; 28(11):1302-1311. PubMed ID: 31566079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.